- Report
- August 2023
- 145 Pages
Global
From €2804EUR$3,150USD£2,422GBP
- Report
- March 2022
- 198 Pages
Global
From €3961EUR$4,450USD£3,422GBP
- Report
- November 2023
- 146 Pages
Global
From €3169EUR$3,560USD£2,738GBP
€3961EUR$4,450USD£3,422GBP
- Report
- October 2020
- 120 Pages
Global
From €2225EUR$2,500USD£1,923GBP
- Report
- November 2023
- 160 Pages
Global
From €3204EUR$3,599USD£2,768GBP
- Report
- August 2022
- 120 Pages
Global
From €4006EUR$4,500USD£3,461GBP
- Report
- July 2024
- 326 Pages
China
From €3561EUR$4,000USD£3,076GBP
- Report
- July 2024
- 187 Pages
China
From €1602EUR$1,800USD£1,384GBP
- Report
- September 2023
- 112 Pages
Europe
From €3071EUR$3,450USD£2,653GBP
- Report
- October 2023
- 96 Pages
Global
From €3500EUR$4,212USD£3,130GBP
- Book
- October 2012
- 1570 Pages
The Hepatitis B Vaccine market is a subset of the larger Infectious Disease Testing market. It is focused on the prevention of Hepatitis B, a viral infection that can cause serious liver damage. The vaccine is typically administered to infants and young children, as well as adults at risk of infection. The vaccine is also recommended for healthcare workers and those with multiple sexual partners. The market is driven by the need to protect vulnerable populations from the virus, as well as the increasing prevalence of the disease in certain regions.
Companies in the Hepatitis B Vaccine market include GlaxoSmithKline, Merck & Co., Sanofi Pasteur, and Pfizer. Show Less Read more
